PDSB News and Press, PDS Biotechnology Corporation From 08/24/22

Initial tranche of $25 million provides funding in preparation for registrational trial for lead candidate PDS0101 Conference call scheduled for Thursday, August 25, 2022 at 8:00 AM EDT FLORHAM PARK, N.J., Aug. 24, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (...

Quarterly Loss Was Less Than We Estimated. PDS Biotech reported 2Q22 loss of $5.8 million or $(0.20) per share, beating our estimated loss of $8.8 million or $(0.34) per share. The differences were largely due to R&D expense of $3.7 million compared with our estimate of $5.3 million, as we...

PDS Biotechnology Corporation (PDSB) Q2 2022 Results Earnings Conference Call August 8, 2022, 08:00 AM ET Company Participants Gabrielle DeGravina - Investor Relations, CG Capital Frank Bedu-Addo - Chief Executive Officer Lauren Wood - Chief Medical Officer M...

PDS Biotechnology press release ( NASDAQ: PDSB ): Q2 GAAP EPS of -$0.20 beats by $0.08 . Cash balance as of June 30, 2022 was approximately $53M. “We made tremendous progress this quarter with our lead candidate, PDS0101, across all four ongoing Phase 2 clin...

Announced results from two of the ongoing Phase 2 clinical trials of PDS0101 in multiple, difficult-to-treat HPV16-related cancers presented at the American Society of Clinical Oncology meeting Promising pre-clinical data on universal flu vaccine program presented at American So...

ANIP , APRN , ASRT , BNTX , CLVS , D , DCTH , DTIL , ELAN , ENR , FREY , GOLD , HE , HEP , ITUB , KNDI , KOS , LINC , OTCPK:LKNCY , OSG , PDSB , PLTR , PRTY , RDWR , RETA , SOHU , TGN...

PDS Biotechnology ( NASDAQ: PDSB ) traded higher on Thursday after the biotech announced that an independent panel recommended its VERSATILE-002 trial for lead asset PDS0101 in combination with Merck’s ( MRK ) anti-PD-1 therapy, Keytruda be continued without changes...

FLORHAM PARK, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune &...

FLORHAM PARK, N.J., Aug. 02, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary Versamune &...

FLORHAM PARK, N.J., July 26, 2022 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of molecularly targeted cancer immunotherapies and infectious disease vaccines based on the Company’s proprietary V...